Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Autoimmune Disorder
Neuromyelitis Optica
Neuromyelitis optica spectrum disorder (NMOSD)

Results
Download
Print

Study results

LPS BN40898 SAkuraSky Final Results November 2019 English (PDF, 0.8 MB)

LPS BN40898 SAkuraSky Final Results November 2019 German (PDF, 0.2 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Study results

LPS BN40898 SAkuraSky Final Results November 2019 English (PDF, 0.8 MB)

LPS BN40898 SAkuraSky Final Results November 2019 German (PDF, 0.2 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

For the latest version of this information please go to www.forpatients.roche.com